Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...
Recently reported findings indicate that cenegermin-bkbj ophthalmic solution (Oxervate; Dompé) may perform as an effective ...
Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...
Effective mentorship is crucial for combating burnout and enhancing teaching efficacy, with strategies like precharting, time blocking, and the Eisenhower Decision Matrix (EDM).
Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...
Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...
The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for ...
New grading scales for ocular adverse events in oncology improve clarity and provide drug-dose-modification recommendations, ...
The authors wrote that early diagnosis, adherence to prolonged management, and constant monitoring can allow the cornea to ...
"Lubricating drops" is proposed as a more accurate term, reflecting their primary function of providing lubrication and ...
In the second part, the discussion turns to emerging DED therapies that target tear function and ocular surface homeostasis.
BCVA is inadequate for detecting visual disturbances in conditions like MacTel, which initially affect the parafoveal region.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback